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Insulin analogues in the treatment 
of diabetes in pregnancy
Análogos de insulina no tratamento do diabetes gestacional
Carlos Antonio Negrato1, Renan Magalhães Montenegro Junior2, Lilia Maria 
Von Kostrisch3, Maria Fatima Guedes1, Rosiane Mattar4, Marilia B. Gomes5
SUMMARY
Pregnancy affects both maternal and fetal metabolism, and even in non-diabetic women, it 
exerts a diabetogenic effect. Among pregnant women, 2% to 14% develop gestational diabetes. 
Pregnancy can also occur in women with preexisting diabetes, which may predispose the fetus 
to many alterations in organogenesis, restrict growth, and the mother, to some diabetes-related 
complications, such as retinopathy and nephropathy, or to acceleration of the course of these 
complications, if they are already present. Women with gestational diabetes generally start their 
treatment with diet and lifestyle changes; when these changes are not enough for optimal gly-
cemic control, insulin therapy must then be considered. Women with type 2 diabetes using oral 
hypoglycemic agents are advised to change to insulin therapy. Those with preexisting type 1 
diabetes should start intensive glycemic control. As basal insulin analogues have frequently 
been used off-label in pregnant women, there is a need to evaluate their safety and efficacy. 
The aim of this review is to report the use of both short- and long-acting insulin analogues dur-
ing pregnancy and to enable clinicians, obstetricians, and endocrinologists to choose the best 
insulin treatment for their patients. Arq Bras Endocrinol Metab. 2012;56(7):405-14
Keywords
Type 1 diabetes; type 2 diabetes; gestational diabetes; insulin analogues; insulin lispro; insulin aspart; insulin glulisine; 
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SUMÁRIO
A gravidez afeta tanto o metabolismo materno quanto o fetal e, mesmo em mulheres não dia-
béticas, apresenta um efeito diabetogênico. Entre as mulheres grávidas, 2% a 14% desenvol-
vem o diabetes gestacional. A gravidez pode ocorrer também em mulheres já diabéticas, o que 
pode predispor o feto a muitas alterações na organogênese, restrição de crescimento e a mãe a 
algumas complicações relacionadas ao diabetes, tais como retinopatia e nefropatia, ou acelerar 
o curso dessas complicações se já estiverem presentes. Pacientes com diabetes gestacional 
geralmente iniciam seu tratamento com dieta e mudanças no estilo de vida; porém, quando 
essas medidas falham em atingir um controle glicêmico adequado, a insulinoterapia deve ser 
considerada. Pacientes com diabetes tipo 2 em uso de hipoglicemiantes orais são aconselhadas 
a iniciar o uso de insulina. Pacientes com diabetes tipo 1 preexistente devem iniciar um controle 
glicêmico estrito. Em função do fato de os análogos basais de insulina estarem sendo utilizados 
muito frequentemente off-label em pacientes grávidas, faz-se necessário avaliar sua segurança 
e eficácia nessa condição. O objetivo desta revisão é avaliar o uso de tais análogos, tanto de 
ação curta como prolongada, durante a gravidez, para possibilitar médicos clínicos, obstetras 
e endocrinologistas escolher o melhor regime terapêutico para suas pacientes. Arq Bras Endocrinol 
Metab. 2012;56(7):405-14
Descritores
Diabetes tipo 1; diabetes tipo 2; diabetes gestacional; análogos de insulina; insulina lispro; insulina aspart; insulina 
glulisine; insulina glargine; insulina detemir
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IntRODUctIOn
Normal pregnancy is a condition characterized by a series of complex hormonal adaptations that 
occur to ensure that sufficient glucose is available to 
meet the nutritional requirements of the growing fetus 
without causing maternal hypoglycemia (1). As normal 
pregnancy progresses, there is an increase in insulin 
resistance that may result in gestational diabetes (2). 
Pregnancy can also occur in women with preexisting 
diabetes. A significant increase in preexisting diabetes 
in pregnant women has been observed in the USA 
bet ween 1999 and 2005, rising from 10% to 21% (3). 
Pregestational diabetes, both type 1 and type 2, can 
cause alterations in fertilization, throughout pregnancy, 
and even after delivery. It can predispose the fetus to 
many alterations in organogenesis, restrict its growth, 
and predispose the mother to some diabetes-related 
complications, such as retinopathy and nephropathy, or 
accelerate the course of these complications, if they are 
already present. Gestational diabetes generally leads to 
fetal growth alterations (2). 
Pregnant women with diabetes present increased 
risk of complications, and their offspring, of neonatal 
morbidity and mortality. Many population-based stu-
dies have explored the impact of diabetes on pregnancy 
outcomes in women with pregestational (types 1 and 2) 
and gestational diabetes (4). Poor pregnancy outcomes, 
such as increased risks of congenital malformations, 
preterm delivery, fetal and neonatal loss, pre-eclampsia, 
Cesarean section and maternal morbidity and mortality, 
occur in one in every four women with pregestational 
diabetes (5,6). Recently, the incidence of type 2 diabe-
tes has increased in parallel with the growing prevalen-
ce of obesity, with more cases of type 2 diabetes being 
diagnosed in pregnant women, even in adolescents and 
young adults (3). Pregnancy outcomes in women with 
type 1 and type 2 diabetes are still poor, and they are si-
milar in both types of diabetes; some studies have even 
found the same or worse rates of adverse outcomes in 
women with type 2 diabetes (6). The presence of ges-
tational diabetes can result in birth injuries, shoulder 
dystocia, macrosomia, and neonatal hypoglycemia, as 
well as increased perinatal morbidity and mortality (7).
The aim of this review is to review the literature on 
the current use of both short- and long-acting insu-
lin analogues during pregnancy, regarding their safety 
and efficacy, and to enable clinicians, obstetricians, and 
endocrinologists to choose the best insulin treatment 
protocol to achieve and maintain normal blood glucose 
levels in all diabetic pregnancies.
ADveRSe OUtcOMeS In pRegnAncIeS Of 
wOMen wIth DIAbeteS
Hyperglycemia, a hallmark of diabetes, is a major cause 
of maternal and fetal morbidity, since excessive blood 
glucose can alter maternal metabolism in many ways, 
and can have teratogenic effects in the fetus, which 
frequently complicate diabetic pregnancies (1,2). The 
most common adverse outcomes found in pregnancies 
of women with diabetes are fetal and neonatal losses; 
stillbirths; a great variety of congenital abnormalities 
and malformations; premature delivery (delivery oc-
curring before 37 weeks of gestation); macrosomia 
(defined as a birth weight above 4 kg and/or > 90th 
percentile weight for gestational age), which is associa-
ted with several obstetric complications; hypertension; 
pre-eclampsia; hypoglycemia; and higher rates of ma-
ternal and fetal mortality (4,5).
Pregnancy loss is significantly higher among women 
with diabetes compared with the non-diabetic popu-
lation (4). Recently, a population-based cohort study 
conducted in the UK by Casson and cols. has shown 
that women with type 1 diabetes have greater risk of 
late fetal loss, presenting a four- to five-fold increase in 
perinatal death, and a four- to six-fold increase in the 
rate of stillbirths (8) compared with the general popu-
lation. Neonatal mortality is also about 15-fold higher 
among infants of diabetic mothers when compared 
with the general population (4). The increased risk of 
congenital abnormalities found in diabetic mo thers 
seems to be associated with poor metabolic control 
during organogenesis, which occurs in the first trimes-
ter of pregnancy, probably due to the negative impact 
the hyperglycemic milieu has in the growing fetus (9). 
Congenital malformations of all types have an incidence 
four to ten times greater in pregnant women with dia-
betes (7). The major congenital malformations found 
among offspring of women with diabetes are bone mal-
formations, congenital heart disease, and neural tube, 
cleft lip and palate-associated anomalies (6,10). These 
major congenital abnormalities are important contribu-
tory factors for the high mortality rates found in infants 
of women with diabetes (8). Preterm delivery is four to 
five times more frequent among mothers with diabetes 
(4). Preterm infants, born to women with any type of 
diabetes, have much greater risk of presenting a wide 
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range of complications, such as intrauterine growth 
restriction, low birth weight, respiratory distress syn-
drome, hypoglycemia, hypocalcemia, polycythemia, 
intrauterine death, hyperbilirubinemia, several types of 
malformations, hypertrophic cardiomyopathy, and as-
phyxia, compared with those born to women without 
diabetes (4).
Glucose is transported freely across the placenta by 
facilitated diffusion; in the presence of maternal hyper-
glycemia, large amounts of glucose reach the fetus, lea-
ding to fetal hyperinsulinemia, which causes fetal over-
growth and/or macrosomia. Besides hyperglycemia, 
high levels of other metabolic fuels, such as some ami-
noacids and free fatty acids, might as well increase fe-
tal insulin secretion and lead to macrosomia (10). The 
rates of macrosomia are 3.5-4.5 times greater among 
infants of women with pregestational diabetes than 
those found in infants born to non-diabetic mothers 
(11). Macrosomia is associated with several obstetric 
complications, such as higher rates of Cesarean section, 
shoulder dystocia, chorioamnionitis, severe perineal la-
cerations, and postpartum hemorrhage (11). Morbidity 
and mortality rates are also higher among pregnant wo-
men with diabetes. Rates of pre-eclampsia (12.7%), Ce-
sarean sections (44.3%), and maternal mortality (0.6%) 
found among women with type 1 diabetes are consi-
derably greater than in the general population. Hyper-
tension and postpartum hemorrhage are more likely to 
be found in pregnancies complicated by diabetes (12). 
Pregnant women with type 1 diabetes present a death 
rate 109 times greater than the general population, and 
3.4 times greater than in non-pregnant type 1 diabetic 
women (13).
Changes in glucose disposal and insulin kinetics 
seen in pregnancy have special importance for women 
with pregestational diabetes because hypoglycemia, 
many times of severe intensity, can generally occur in 
early pregnancy, a period when insulin requirements 
may decrease, possibly because of nausea and vomiting, 
compared with prepregnancy and the second half of 
pregnancy; it is a dangerous condition that can have 
important after-effects, both to the mother and to the 
fetus (14).
tReAtMent Of DIAbeteS In pRegnAncY
The treatment of diabetes in pregnancy requires lifesty-
le modifications, medical nutrition therapy and physical 
activities, along with pharmacological treatment that 
should promote normal or near-normal glycemic levels 
and adequate weight gain. During the second and third 
trimesters of pregnancy, there is a steady increase in in-
sulin resistance. This results in fasting and postprandial 
hyperglycemia, hyperlipidemia, and hyperaminoacide-
mia. These metabolic disturbances are the targets of 
therapeutic interventions performed in diabetic preg-
nancies in order to obtain good metabolic control (2).
InSUlIn theRApY DURIng pRegnAncY 
Insulin is the treatment of choice for any type of diabe-
tes during pregnancy; most of insulin preparations used 
today have been shown to be safe and promote good 
glycemic control during pregnancy. If the patient has 
pre-existing type 2 diabetes being treated with oral hy-
poglycemic agents, she is advised to discontinue these 
medications and start using insulin, as soon as a possi-
ble pregnancy is diagnosed; if the pregnancy is planned 
she should be advised to start using insulin even before 
she becomes pregnant (15). 
Before the discovery of insulin in 1922, the outcomes 
of less than 100 pregnancies were reported in women 
with diabetes. The rates of mortality both for the mo-
thers and infants were very high, being greater than 90% 
for infants and 30% for the mothers, respectively (16).
Lower infant mortality rates started to be noted af-
ter 1980, when the importance of more strict control 
of maternal plasma glucose levels started to be stressed, 
and self-monitoring of blood glucose and the evalua-
tion of hemoglobin A1C became available. After then, 
near-normal blood glucose levels became possible to 
be achieved and maintained throughout pregnancies of 
women with diabetes; consequently, ever since, perina-
tal mortality rates have reached levels observed in the 
general non-diabetic population (16). 
The targets for glycemic control during pregnancy 
are pre-breakfast plasma glucose levels of 60-90 mg/dL 
(3.3-5.0 mmol/L), preprandial levels of 60-105 mg/
dL (3.3-5.8 mmol/L), one-hour postprandial levels < 
140 mg/dL (7.8 mmol/L), two-hour postprandial le-
vels < 120 mg/dL (6.7 mmol/L), and levels between 2 
am to 4 am > 60 mg/dL (3.3 mmol/L); these targets 
for one-hour postprandial levels might be even lower, 
preferably below 120 mg/dL (6.66 mmol/L) in order 
to avoid macrosomia. All these levels should be obtai-
ned without the occurrence of hypoglycemia (15,16).
The treatment of any type of diabetes in pregnancy 
should be done with the use of non-immunogenic 
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insulins, that is not able to cross the placenta unless 
bound to IgG antibodies. In contrast, facilitated diffu-
sion helps glucose cross the placenta; therefore, mater-
nal high blood glucose levels would stimulate the fetal 
pancreas to produce high amounts of insulin and, con-
sequently, cause macrosomia (17). 
The transfer of insulin bound to immunoglobulin 
through the placenta has been associated with fetal ma-
crosomia in mothers with near-normal glycemic levels 
during gestation (18). However, Jovanovic and cols. 
have found that only very strict blood glucose control, 
reached by one-hour postprandial glucose levels lower 
than 120 mg/dL (6.66 mmol/L), but not lower in-
sulin antibody levels, were correlated with lower fetal 
weight and lower rates of macrosomia. This means that 
adequate one-hour postprandial glucose levels, but not 
insulin antibodies against exogenous insulin, can in-
fluence infant birth weight (18).
Insulin requirements rise during pregnancy becau-
se of progressive increase in insulin resistance generally 
associated with weight gain and decreasing physical 
activity. Insulin requirements grow progressively in a 
rate of 0.7, 0.8, and 0.9 to 1.0 units per kilogram of 
pregnant weight, in the first, second, and third trimes-
ter, respectively. There is a transient drop in insulin re-
quired doses in the first trimester, probably because of 
nausea and vomiting (16). 
RApID-ActIng InSUlIn AnAlOgUeS 
Insulin lispro
In 1996, lispro became commercially available for clini-
cal use. It is an analogue of human insulin obtained by 
means of recombinant DNA technology that modifies 
the beta-chain of human insulin by inverting the po-
sition of lysine from B29 to B28, with that of proline 
from B28 to B29. Insulin lispro exists naturally as a he-
xamer, but dissociates instantaneously into monomeric 
subunits when injected in the subcutaneous tissue (19).
Action begins in 15 minutes or less after the in-
jection, and has its peak between 30-90 minutes, las-
ting from four to six hours. It also does not cross the 
placental barrier to the fetus, except with high-doses 
used during placental insulin studies (19). Compared 
with regular human insulin, its use is associated with 
lowering in postprandial glucose levels of 27-36 mg/
dL (1.5 to 2.0 mmol/L), a 0.3% to 0.5% reduction in 
HbA1c, and a 20% to 30% reduction in hypoglycemic 
episodes during the day, but especially during the ni-
ght. Insulin lispro can be used immediately before or 
after a meal (19). 
Insulin aspart
Insulin aspart was approved by the Food and Drug 
Administration for clinical use in 1999. It is also ob-
tained by means of recombinant DNA technology, by 
replacing proline in the B28 position with negatively-
charged aspartic acid. There is a rapid dissociation in 
monomers because of charge repulsion in the tertiary 
structure. Its action starts fifteen minutes or less after 
injection, and the peak is observed after 31 to 70 min-
utes of the injection; action lasts from 4 to 6 hours. 
It lowers postprandial plasma glucose by 27 mg/dL 
(1.5 mmol/L), HbA1c by 0.12%, and hypoglycemic 
episodes by 50%. Compared with regular human in-
sulin in clinical trials performed with non-pregnant 
healthy volunteers, and patients with type 1 and type 
2 diabetes, insulin aspart showed faster onset of action 
and promoted lower postprandial glucose levels (20). 
Insulin aspart at doses 3 to 200 times the typical hu-
man subcutaneous doses caused fetal malformations 
in studies of reproduction and teratology performed 
in animals. These adverse effects might be caused by 
maternal hypoglycemia occurring with these high and 
supraphysiological doses (21). 
Insulin glulisine 
Insulin glulisine is a rapid-acting analogue available for 
clinical use since 2004, with an action profile similar to 
that of insulin lispro and aspart. It is produced by re-
placing lysine in the B29 position by glutamic acid and 
asparagine in the B3 position by lysine. It has a faster 
onset of action and shorter duration of action than re-
gular human insulin. It starts to act 10-15 minutes after 
the injection, and the peak occurs from 30-60 minutes, 
with its action lasting 4-5 hours. It has been shown to 
be as safe as insulin lispro, or to be regular in non-preg-
nant patients with type 1 or type 2 diabetes (21).
RApID-ActIng InSUlIn AnAlOgUeS In 
pRegnAncY
Because of the changes in insulin needs that occur du-
ring pregnancy, short-acting insulins are generally ne-
cessary to control postprandial hyperglycemia, and to 
optimize the doses of intermediate-acting insulins in 
Insulin analogues in pregnancy
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order to maintain an adequate insulin basal rate. Due 
to their fast onset and short duration of action, rapid-
-acting insulin analogues are useful in pregnancy be-
cause they can reduce postprandial glucose excursions 
and prevent preprandial hypoglycemia. Compared 
with soluble human insulin outside of pregnancy, the 
rapid-acting analogues have been associated with better 
post prandial glucose control, lower HbA1c levels, and 
reduced risk of hypoglycemia (21). 
The human placenta cannot be crossed by rapid-
-acting insulin analogues, as evidenced by many stu-
dies. Therefore, they can be considered as therapeutic 
agents in the treatment of pregnancies complicated by 
diabetes (18,21). 
Insulin lispro
The first report on the safety and efficacy of insulin 
lispro in pregnancy was published in 1999; this study 
performed in women with gestational diabetes showed 
insulin lispro to be more efficacious in normalizing 
blood glucose levels than regular human insulin; in ra-
pidly lowering postprandial glucose levels, and in de-
creasing hemoglobin A1C levels, with less hypoglyce-
mia, and without increasing the levels of anti-insulin 
antibody (22). The safety and efficacy of Insulin lispro 
was shown in some trials, and in some case reports per-
formed with pregnant women with gestational diabetes 
(22,23,25) and type 1 diabetes (24,26,27,29-32). It 
was also found not to cross the placenta (36). These 
data support that insulin lispro can be considered as a 
treatment option in women with gestational and type 1 
diabetes that do not reach the target of glycemic con-
trol with regular human insulin (21).
In 1997, the safety of insulin lispro in pregnancy was 
questioned after the birth of two infants with congenital 
malformations whose mothers were in insulin treatment 
with lispro during pregnancy. This raised a question 
among researchers whether insulin lispro might have 
teratogenic effects on the fetus. Although pregnant 
women were excluded from the initial clinical trials tes-
ting insulin lispro, some women became unexpectedly 
pregnant, and 19 infants were born. Of these births, 18 
children were healthy and one had congenital malfor-
mation (37). Subsequently, Wyatt and cols. performed a 
multicenter, multinational retrospective analysis of 500 
pregnancies in which women were treated with insulin 
lispro before and during organogenesis; there were 27 
malformed infants (5.4%); interestingly, this incidence 
of malformations was not different from that found in 
the general population, and all children that had any 
kind of congenital anomaly were born to mothers who 
had high levels of HbA1c, at least 2 SDs above the mean 
of a non-diabetic population. This proved that inade-
quate glycemic control, instead of insulin lispro, was 
responsible for these malformations in this population 
of pregnant women with type 1 diabetes (32).
Insulin aspart 
Pettitt and cols. (28) conducted the first clinical stu-
dy to compare the short-term efficacy of insulin aspart, 
regular insulin, or no insulin in fifteen patients with 
gestational diabetes. Postprandial glycemic levels were 
significantly improved by insulin aspart compared with 
no exogenous and regular insulin. In a second study, 
the same investigators then analyzed a sample of twen-
ty seven women randomized to receive either insulin 
aspart or regular insulin for prandial treatment of their 
hyperglycemia. Both groups maintained good glycemic 
control. Insulin aspart was effective in reducing post-
prandial glucose concentration from baseline. Insulin 
aspart treatment showed significantly lower C-peptide 
values than regular insulin, and no major hypoglycemic 
events were reported. Birth weight was similar in both 
groups with no case of macrosomia reported. This stu-
dy showed that insulin aspart was comparable with re-
gular human insulin in pregnant women with gestatio-
nal diabetes regarding safety and effectiveness, and that 
it was more effective in providing postprandial glycemic 
control (38).
Recently, the largest randomized controlled clini-
cal trial using an insulin analogue was conducted in 17 
countries at 90 centers with a total of 322 type 1 dia-
betic women who received either regular human insulin 
or insulin aspart during pregnancy, with NPH (neutral 
protamine Hagedorn) insulin as basal-bolus insulin 
regimen. There have been no insulin-associated mater-
nal or fetal complications, and no evidence that insulin 
aspart is teratogenic (34,35).
Insulin glulisine
There are no clinical trials using insulin glulisine in 
pregnancy so far, so it cannot be recommended in preg-
nancy (21).
Finally, it should be stated that many studies and 
case reports, most of them with small number of pa-
tients, have been conducted with the rapid-acting ana-
Insulin analogues in pregnancy
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logues lispro and aspart, which have shown to be safe 
and effective in the treatment of pregnant women with 
gestational and type 1 diabetes (22-35).
Table 1 shows the results of fourteen articles report-
ing on 2,069 pregnant diabetic women, 1,794 with 
type 1 diabetes, and 275 cases of gestational diabetes. 
Among these patients, 831 were treated with lispro and 
498 with aspart. Although not all reports were con-
ducted comparing the outcomes found in these patients 
with those found in patients treated with human regu-
lar insulin, it can be concluded that both analogues, 
lispro and aspart, are safe and, in several aspects, more 
efficient than human regular insulin in the treatment of 
pregnant women with diabetes. 
lOng-ActIng InSUlIn AnAlOgUeS 
Insulin glargine 
Insulin glargine is a long-acting insulin analogue ap-
proved for use in the United States and Europe in 2000 
as basal insulin. Insulin glargine has a glycine substi-
tution in the α-chain at position 21 and two arginine 
molecules attached to the β-chain terminal at position 
30. These changes shift the isoelectric point from pH 
5.4 to 6.7, decreasing the solubility in the subcutane-
ous tissue and conferring greater stability and leading 
to longer action. It starts to act about 90 minutes after 
injection, action lasts 24 hours, and has no peak of ac-
table 1. Use of short-acting insulin analogues lispro and aspart in pregnancy 
Studies number of patients type of DM lispro Aspart Regular Outcomes
Jovanovic and cols. (22) 42 GDM 19 0 23 ↓ PP with lispro
Bhattacharyya and cols. (23) 157 GDM 68 0 89 ↓ HbA1c with lispro
Persson and cols. (24) 33 T1D 16 0 17 ↓ PP and HbA1c with lispro; WR
Mecacci and cols. (25) 49 GDM 20 0 19 ↓ PP with lispro
Loukovaara and cols. (26) 69 T1D 36 0 33 ↓ PP and HbA1c with lispro; WR
Garg and cols. (27) 62 T1D 62 0 0 ↓ HbA1c with lispro; 24% LGA; 2CM
Pettitt and cols. (28) 27 GDM 0 13 14 ↓ PP with aspart
Masson and cols. (29) 76 T1D 76 0 0 6 SA; 7 LGA; 4 CM; 6 WR
Carr KJ and cols. (30) 9 T1D 9 0 0 Pre-meal = to PP insulin injection
Cypryk K and cols. (31) 71 T1D 25 46 0 No difference
Wyatt and cols. (32) 500 T1D 500 0 0 27 CM when HbA1c > 2 SD mean nl in 1st trim
Hod and cols. (33) 330 T1D 0 125 125 ↓ Hypo and hyperglycemia
Mathiesen and cols. (34) 322 T1D 0 157 165 ↓ PP and hypoglycemia with aspart
Hod and cols. (35) 322 T1D 0 157 165 ↓ Fetal losses and preterm with aspart
T1D: type 1 diabetes mellitus; GDM: gestational diabetes mellitus; PP: postprandial glucose levels; HbA1C: glycosylated hemoglobin; LGA: large for gestational age infant; CM: congenital 
malformations; SA: spontaneous abortion; WR: worsening of retinopathy; SD: standard deviation.
tion. It lowers both fasting and postprandial glucose 
levels and is associated with less hypoglycemic events 
and lower weight gain (21).
Insulin detemir 
Insulin detemir is also a long-acting insulin analogue 
commercially available since 2004; it is soluble and 
obtained by the replacement of threonine in β-chain 
at position 30 and the acylation of lysine at position 
29 with a molecule of myristic fatty acid formed by a 
fourteen-carbon chain. This leads to increased hexamer 
stability, stronger and stable binding to albumin both at 
the subcutaneous injection site and in the circulation. It 
has a peakless action sustained for 18-20 hours, a capa-
c i ty of lowering both fasting and postprandial glucose 
levels, and it is also associated with less hypoglycemic 
events and lower weight gain. The benefits of using in-
sulin detemir, such as improved glycemic control, lower 
within-subject variation, reduced nocturnal hypoglyce-
mic events and no weight gain, have been demonstrat-
ed basically in patients with type 1 diabetes (21). 
lOng-ActIng InSUlIn AnAlOgUeS In 
pRegnAncY 
Regarding the long-acting insulin analogues, there is a 
growing body of studies suggesting that they could also 
be helpful in the treatment of pregnant women with 
diabetes (21).
Insulin analogues in pregnancy
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Insulin glargine
It should be noted that insulin glargine causes a six-fold 
increase in IGF-I activity compared with human insu-
lin. No large randomized clinical trials with insulin glar-
gine used during pregnancy have been done up to now 
(21). It was also proven that insulin glargine does not 
cross the placenta (39), and many studies with small 
number of patients have shown the safety and efficacy 
of its use in pregnancy (40-54,56). 
Negrato and cols. have conducted a prospective co-
hort study analyzing the outcomes of 56 women with 
pregestational and 82 with gestational diabetes treated 
with NPH or glargine during their pregnancies. Mater-
nal complications were found more frequently in women 
with pregestational diabetes treated with NPH compa-
red with those that were treated with glargine. In wo-
men with gestational diabetes treated with NPH, it was 
observed an increased incidence of new-onset pregnancy 
hypertension, micro- and macroalbuminuria, as well as 
occurrence of mild and frequent hypoglycemia, compa-
red with those women treated with glargine. Among ne-
onatal outcomes, significantly higher rates of NICU ad-
mission and fetal death were observed in infants born to 
women with pregestational diabetes treated with NPH 
insulin. Among infants born to women with gestatio-
nal diabetes, the occurrence of jaundice and congenital 
malformations were significantly more frequent in the 
NPH-treated group versus the insulin glargine-treated 
group. These results led to the conclusion that the use 
of insulin glargine during pregnancy, from preconcep-
tion to delivery, showed to be safe since it was associated 
with decreased maternal and neonatal adverse outcomes 
when compared with NPH insulin-treated patients (56). 
Recently, Pollex and cols. have performed a meta-
-analysis of eight studies reporting on a total of 702 
women with pregestational or gestational diabetes tre-
ated with either insulin glargine (n = 331) or NPH in-
sulin (n = 371). There were no statistically significant 
differences in the occurrence of fetal outcomes with the 
use of insulin glargine compared with NPH insulin in 
these studies (58). 
Insulin detemir
Animal reproduction studies have not revealed any 
differences between insulin detemir and human insulin 
regarding embryotoxicity and teratogenicity (21).
There is an ongoing randomized, controlled, open-
-label, multicenter, multinational trial comparing in-
sulin detemir with NPH insulin, and both with insu-
lin aspart, in women with type 1 diabetes planning a 
pregnancy (n = 306) or already pregnant (n = 164). 
The inclusion criteria includes diagnosis of type 1 dia-
betes > 12 months duration; screening HbA1c ≤ 9.0% 
for women recruited during prepregnancy or pregnant 
for 8-12 weeks, and HbA1c ≤ 8.0% at randomization. 
At confirmation of pregnancy, all subjects must have 
HbA1c ≤ 8.0%. The exclusion criteria include impai-
red hepatic function, cardiac problems, and uncontrol-
led hypertension. From the participating patients, 152 
were treated with detemir, and 158 with NPH insulin. 
The results found so far that detemir insulin is not in-
ferior compared with NPH insulin in pregnant women 
with type 1 diabetes. This study will hopefully elucidate 
the safety and efficacy of the basal insulin analogue de-
temir in diabetic pregnancy (57).
pOtentIAl RISKS ASSOcIAteD wIth the USe Of 
InSUlIn AnAlOgUeS In pRegnAncY
There are many reasons to be aware of undesirable 
increased IGF-1 activity during pregnancy, a period 
when the maternal reproductive system suffers drama-
tic changes to support the development of the embryo 
and the fetus. Important safety concerns with the use 
of the new insulin analogues in pregnancy have been 
their capacity of causing mitogenicity, immunogenicity, 
transplacental passage of the antibody-analogue com-
plex and, finally, an increased risk of teratogenicity and 
embryotoxicity (10,21,59).
Mitogenicty was observed with the analogue Asp 
B10 which showed excessive development of tumors in 
the mammary glands in female Sprague Dawley rats. It 
was demonstrated that Asp B10 had increased binding 
affinity to IGF-I receptors (21). Insulin only crosses 
the placenta when linked to IGG antibodies. Therefo-
re, insulin antibodies are a concern because they could 
facilitate insulin crossing of the placental barrier. Ho-
wever, insulin antibodies to insulin lispro and glargi-
ne have shown to be similar levels, or less frequently 
found when compared with regular insulins (36,39). 
Women with diabetes and poor glucose control present 
higher incidence of spontaneous miscarriage during 
early pregnancy probably because of malformations of 
the fetuses when compared with non-diabetic pregnant 
women. The underlying factors that contribute for the 
occurrence of abortions and malformations are still not 
clear. Possibly inherited genetic abnormalities of the 
fetus, lack or low levels of insulin in maternal serum 
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mainly in those pregnant women with type 1 diabetes, 
and maybe some embryotoxic effects that the diabetic 
serum can exert on the fetus (60). 
Although not found by clinical reports thus far, the-
re are medical reasons to be concerned about the use 
of insulin analogues during pregnancy because of their 
affinity to the IGF-I receptor: this affinity is 5.9-fold 
greater for insulin analogue Asp B10; 6-fold greater for 
insulin glargine; and 1.5-fold greater for lispro, compa-
red with human insulin (39,58). 
Alterations in IGF-I functions could cause sponta-
neous miscarriage, preeclampsia, and embryo defects. It 
is supposed that altered insulin and IGF-I serum levels 
could account for dysregulation of trophoblast prolife-
ration and invasion (60). An insulin analogue that has 
high affinity for the IGF-I receptor, such as glargine, 
could exert some influence in the natural processes me-
diated by IGF-I. It is of note that IGF-I can bind to the 
insulin receptor, and insulin is capable of binding to the 
IGF-I receptor. However, natural insulin binds to IGF-I 
receptor with 1,000-fold lower affinity than insulin bin-
ding to the insulin receptor, and insulin has a 1,000-fold 
lower affinity for the IGF-I receptor than IGF-I (39,58).
All the new insulin analogues have modifications in 
their amino acid sequences. These modifications in their 
structure can sometimes lead to enhanced or reduced 
affinity for the insulin receptor and IGF-I receptor.
The long-acting insulin analogues detemir and glar-
gine are interesting alternatives for the administration 
of basal insulin, but there were no clinical trials with 
robust results that could assess the long-term safety and 
efficacy of these new long-acting insulin analogues. 
Table 2 shows the results of seventeen articles repor-
ting on 1,032 pregnant diabetic women with type 1, 
table 2. Use of long-acting insulin analogues glargine and detemir in pregnancy
Studies number of patients
type of 
DM glargine Detemir nph Outcomes
Devlin and cols. (40) 1 T1D 1 0 Better glycemic control vs. NPH 
Holstein and cols. (41) 1 T1D 1 0 Better glycemic control vs. NPH 
Woolderink and cols. (42) 7 T1D 7 0 Delivery at 37-40 weeks; no CM
Di Cianni and cols. (43) 5 T1D 5 0 No CM
Dolci and cols. (44) 1 T1D 1 0 Better glycemic control vs. NPH
Graves and cols. (45) 4 GDM 4 0 No nocturnal hypoglycemia
Caronna and cols. (46) 1 T1D 1 0 No adverse outcomes
Torlone and cols. (47) 6 T1D 6 0 No adverse outcomes
Pöyhönen-Alho (48) 100 T1D 42 0 49 Greater ↓ in HbA1c with glargine similar rates of glycemic control and 
hypoglycemia 
Price and cols. (49) 32 10 T1D,
22 GDM
32 0 32 No ↑ in hypoglycemia, mean blood glucose, HbA1c, gestational age, 
macrosomia and neonatal morbidity
Gallen and cols. (50) 115 T1D 115 0 0 Better glycemic control with glargine < HbA1c at the end of the 1st trimester 
No increase in CM rates  
↓ Severe hypoglycemia
Imbergamo and cols. (51) 30 T1D 15 0 15 Better glycemic control vs. NPH
Higher frequency of femoral length < 50th percentile with glargine 
Di Cianni and cols. (52) 107 T1D 107 0 0 No influence in birth weight or increase in adverse outcomes.
Fang and cols. (53) 112 T1D, T2D 
and 59 
GDM
52 0 60 No significant differences in rates of maternal and neonatal complications 
↓ macrosomia in pre-existing diabetes with glargine 
↓ neonatal hypoglycemia and hyperbilirubinemia with glargine vs. NPH
Smith and cols. (54) 52 T1D, T2D, 
DMG
27 0 25 No differences in mode of delivery,  average birth weight, or neonatal 
outcomes between glargine vs. NPH 
Lapolla and cols. (55) 10 T1D 0 10 0 No adverse outcomes
Negrato and cols. (56) 138 T1D, 
T2D,
55 DMG
55 0 83 ↑ rates of NICU admission and fetal death in infants born to women with 
pregestational diabetes NPH-treated Infants born to women with GDM, had 
↑ rates of jaundice and CM in the NPH vs. glargine group  
↓ dose of insulin and fewer maternal hypoglycemia in glargine vs. NPH
Mathiesen and cols. (57) 310 T1D 0 152 158 Detemir is not inferior to NPH in any of the evaluated outcomes
T1D: type 1 diabetes mellitus; T2D: type 2 diabetes; GDM: gestational diabetes mellitus; PP: postprandial glucose levels; HbA1C: glycosylated hemoglobin; CM: congenital malformations; NICU: 
neonatal intensive care unit; NPH: neutral protamine Hagedorn.
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type 2, and gestational diabetes. Among these patients, 
860 were treated with glargine, and 162 with detemir 
insulin. Although not all reports were conducted com-
paring the outcomes in these patients with those in pa-
tients treated with NPH insulin, it can be concluded 
that both analogues, glargine and detemir seem to be 
safe and in, several aspects, more efficient than NPH 
insulin in the treatment of diabetes in pregnancy. 
Finally, it is of note that the rapid-acting analogues 
lispro and aspart, and the long-acting insulin detemir 
are assigned a use-in-pregnancy category “B” rating, 
meaning that clinical studies in pregnant women have 
not shown increased risks to the fetus. Insulin glulisine 
has not been evaluated in pregnancy and is assigned a 
category “C” rating, as well as insulin glargine, indi-
cating that the drug should be used during pregnancy 
only if the potential benefits to the mother justify the 
potential risks to the fetus (10). 
cOnclUSIOnS
Pregnancies complicated by diabetes are still associa-
ted with excessive adverse fetal, neonatal, and maternal 
outcomes that could be avoided by optimum glycemic 
control. The new insulin analogues present undoubted 
advantages in reducing the risk of hypoglycemia, mainly 
during the night, and in promoting a more physiolo-
gical glycemic profile in pregnant women with type 1, 
type 2, or gestational diabetes. The rapid-acting analo-
gues lispro and aspart seem to be safe and efficient in 
reducing postprandial glucose levels even more efficien-
tly than regular human insulin, with less hypoglycemia. 
The long-acting insulin analogues do not have a 
pronounced peak effect as NPH insulin, and are suppo-
sed to cause less hypoglycemia, mainly during the night. 
However, the safety of these insulin analogues needs to 
be further studied and better established in pregnant 
women. Future studies are warranted and must also in-
clude the development of insulins that perfectly match 
physiological insulin profiles during pregnancy. 
Disclosure: no potential conflict of interest relevant to this article 
was reported. 
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